Development of torcetrapib, a lipid-lowering drug, abandoned.
出版信息
Prescrire Int. 2007 Jun;16(89):114.
PMID:17590910
Abstract
摘要
相似文献
1
Development of torcetrapib, a lipid-lowering drug, abandoned.
Prescrire Int. 2007 Jun;16(89):114.
2
The failure of torcetrapib: was it the molecule or the mechanism?
Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):257-60. doi: 10.1161/01.ATV.0000256728.60226.77.
3
Effect of torcetrapib on the progression of coronary atherosclerosis.
N Engl J Med. 2007 Mar 29;356(13):1304-16. doi: 10.1056/NEJMoa070635. Epub 2007 Mar 26.
4
New drug fizzles at raising HDL. Tried-and-true strategies are still excellent ways to boost good cholesterol.
Harv Heart Lett. 2007 Mar;17(7):1-2.
5
Torcetrapib and coronary events.
N Engl J Med. 2008 Apr 24;358(17):1863; author reply 1863-4.
6
Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
Cardiol Clin. 2008 Nov;26(4):537-46. doi: 10.1016/j.ccl.2008.06.005.
7
Effects of torcetrapib in patients at high risk for coronary events.
N Engl J Med. 2007 Nov 22;357(21):2109-22. doi: 10.1056/NEJMoa0706628. Epub 2007 Nov 5.
8
Torcetrapib: when global risk reduction goes 'off target'.
Int J Clin Pract. 2008 Feb;62(2):173-4. doi: 10.1111/j.1742-1241.2007.01687.x.
9
Drug designed to raise HDL levels falls down.
J Clin Invest. 2007 Feb;117(2):282. doi: 10.1172/JCI31253.
10
HDL cholesterol and atherosclerosis.
Lancet. 2007 Jul 14;370(9582):107-108. doi: 10.1016/S0140-6736(07)61063-0.
Zotero 插件